67 related articles for article (PubMed ID: 27826135)
1. Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.
Qu Y; Zhang C; Du E; Wang A; Yang Y; Guo J; Wang A; Zhang Z; Xu Y
Med Sci Monit; 2016 Nov; 22():4254-4260. PubMed ID: 27826135
[TBL] [Abstract][Full Text] [Related]
2. Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer.
Sharma A; Dubey R; Asati V; Baweja GS; Gupta S; Asati V
Mol Divers; 2024 Apr; ():. PubMed ID: 38642309
[TBL] [Abstract][Full Text] [Related]
3. Expression and function of PIM kinases in osteosarcoma.
Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q
Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617
[TBL] [Abstract][Full Text] [Related]
4. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
[TBL] [Abstract][Full Text] [Related]
5. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
Atalay P; Ozpolat B
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
[TBL] [Abstract][Full Text] [Related]
6. Yin/Yang associated differential responses to Psoralea corylifolia Linn. In rat models: an integrated metabolomics and transcriptomics study.
Zhang ML; Zhao X; Li WX; Wang XY; Niu M; Zhang H; Chen YL; Kong DX; Gao Y; Guo YM; Bai ZF; Zhao YL; Tang JF; Xiao XH
Chin Med; 2023 Aug; 18(1):102. PubMed ID: 37592331
[TBL] [Abstract][Full Text] [Related]
7. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.
Zhai Y; Singh P; Dolnik A; Brazda P; Atlasy N; Del Gaudio N; Döhner K; Döhner H; Minucci S; Martens J; Altucci L; Megchelenbrink W; Bullinger L; Stunnenberg HG
Mol Cancer; 2022 Aug; 21(1):166. PubMed ID: 35986270
[TBL] [Abstract][Full Text] [Related]
9. The Role of PIM Kinases in Pediatric Solid Tumors.
Julson JR; Marayati R; Beierle EA; Stafman LL
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892829
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA (FALEC) promotes malignant behaviors of gastric cancer cells by regulating miR-203b/PIM3 axis.
Dong W; Gong M; Xiao J; Li H; Tian M; Wang S
Ann Transl Med; 2022 May; 10(10):579. PubMed ID: 35722357
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review.
Beyer K; Moris L; Lardas M; Haire A; Barletta F; Scuderi S; Molnar M; Herrera R; Rauf A; Campi R; Greco I; Shiranov K; Dabestani S; van den Broeck T; Arun S; Gacci M; Gandaglia G; Omar MI; MacLennan S; Roobol MJ; Farahmand B; Vradi E; Devecseri Z; Asiimwe A; Zong J; Maclennan SJ; Collette L; NDow J; Briganti A; Bjartell A; Van Hemelrijck M;
BMJ Open; 2022 Apr; 12(4):e058267. PubMed ID: 35379637
[TBL] [Abstract][Full Text] [Related]
12. Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors.
Casillas AL; Chauhan SS; Toth RK; Sainz AG; Clements AN; Jensen CC; Langlais PR; Miranti CK; Cress AE; Warfel NA
Oncogene; 2021 Aug; 40(32):5142-5152. PubMed ID: 34211090
[TBL] [Abstract][Full Text] [Related]
13. Expression and ERG regulation of PIM kinases in prostate cancer.
Eerola SK; Kohvakka A; Tammela TLJ; Koskinen PJ; Latonen L; Visakorpi T
Cancer Med; 2021 May; 10(10):3427-3436. PubMed ID: 33932111
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
[TBL] [Abstract][Full Text] [Related]
15. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S; Kumar C; Sathyadevan VK; Simpson BS; Gately KA; Whitaker HC; Heavey S
Signal Transduct Target Ther; 2020 Jan; 5(1):7. PubMed ID: 32296034
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion.
Eerola SK; Santio NM; Rinne S; Kouvonen P; Corthals GL; Scaravilli M; Scala G; Serra A; Greco D; Ruusuvuori P; Latonen L; Rainio EM; Visakorpi T; Koskinen PJ
Cell Commun Signal; 2019 Nov; 17(1):148. PubMed ID: 31730483
[TBL] [Abstract][Full Text] [Related]
17. PIM Kinase as an Executional Target in Cancer.
Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
[TBL] [Abstract][Full Text] [Related]
18. Toll-Like Receptor 4 (TLR4)/Cyclooxygenase-2 (COX-2) Regulates Prostate Cancer Cell Proliferation, Migration, and Invasion by NF-κB Activation.
Wang W; Wang J
Med Sci Monit; 2018 Aug; 24():5588-5597. PubMed ID: 30098292
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
20. Baculoviral IAP Repeat Containing 6 (BIRC6) Is a Predictor of Prognosis in Prostate Cancer.
Zhuang W; Zhang C; Hao F; Sun X
Med Sci Monit; 2018 Feb; 24():839-845. PubMed ID: 29429983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
